About DSANJ

What is DSANJ?

The Drug Seeds Alliance Network Japan (DSANJ) is a program that supports connections between researchers and pharma companies in Japan and the world. It promotes new collaborations, including joint research, to contribute to the development of new drugs.

DSANJ Bio Conference at a Glance

Part of the program is the “DSANJ Bio Conference,” a twice-yearly event that matches researchers who are seeking collaboration with pharma companies and the pharma companies themselves.

DSANJ Bio Conference FY2026: Overview

Purpose Promoting joint research, technology transfer and investment in drug discovery
Program One-on-one meetings (held online) between academia, startups, etc., and pharma companies
Schedule Mid-2026: 10:00–18:00 (JST) on Aug. 25, 26, 27, 31; Sep. 1
Early 2027: 10:00–18:00 (JST) on Jan. 27, 28, 29; Feb. 1, 2
Participants
  • Academia and startups with promising new drug discovery seeds and platform technologies
  • Pharma companies and other organizations seeking drug discovery seeds and platform technologies
Area of focus

  • Categories

    Drug targets; drug seeds (substances); platform technologies for drug discovery; biomarkers; diagnostic drugs and technologies; digital therapeutics; medical devices for use combination with drugs, etc. (i.e., excluding devices designed for use on their own)

  • Modalities

    Low-molecular drugs, antibody drugs, oligonucleotide therapeutics, gene therapy, recombinant protein, cell therapy, AI-powered drug discovery, vaccines, viruses, regenerative medicine, SaMD (treatment apps), digital healthcare, protein-protein interaction inhibitors, etc.

  • Target Disorders

    Metabolic disorders, circulatory disorders, infectious disorders, respiratory disorders, musculoskeletal disorders, cancer and malignant neoplasms, central nervous system disorders, pain, sensory organ disorders, immune system and inflammatory disorders, allergies, skin disorders, digestive and urinary disorders, ob-gyn disorders, rare disorders, etc.

  • Stage of Research Progress

    Basic research; non-clinical POC pending; non-clinical POC obtained, clinical trials pending; clinical trials underway, etc.
Organizers Osaka Chamber of Commerce and Industry (OCCI), Kansai Pharmaceutical Industries Association (to be confirmed)
Co-organizer Osaka Prefecture (to be confirmed)
Support Japan Agency for Medical Research and Development (AMED), Japan Pharmaceutical Manufacturers Association (JPMA), Organization for Small & Medium Enterprises and Regional Innovation, JAPAN (SME SUPPORT JAPAN), Japan External Trade Organization (JETRO) (to be confirmed), Osaka City (to be confirmed)
Special thanks Life Science Innovation Network Japan (LINK-J) (to be confirmed)

DSANJ Bio Conference (FY2010–FY2024): By the Numbers

  • Total 2,146 proposals have submitted
  • Total meetings resulting from conference: 9,811
  • Total 532 pharma companies have participated (40 in FY2025)
  • Total 385 universities, research institutions and startups have participated across Japan and around the world
  • Total 89 collaborations (joint research deals etc.) have been reached　 *FY2024 and later are currently under review

Participant Feedback

DSANJ Bio Conference (2010–2024): By the Numbers

DSANJ Networks: Japanese & Global

We have partnered with 262 universities, research institutions, startups, etc., throughout Japan
We have partnered with 104 institutions in 25 countries